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ABSTRACT 
Due to their extensive use as plasticisers in numerous consumer products, phthalates have be-
come ubiquitous environmental contaminants. An increasing number of epidemiological stud-
ies suggest that exposure to phthalates may be associated with worsening or development of 
airway diseases. Peroxisome Proliferation Activated Receptors (PPAR)s, identified as im-
portant targets for phthalates in early studies in rodent liver, have been suggested as a possible 
mechanistic link. In this review we discuss the likelihood of an involvement of PPARs in 
asthma development and exacerbation due to pulmonary phthalate exposure. First, we go 
through the literature on indoor air levels of phthalates and pulmonary phthalate kinetics. 
These data are then used to estimate the pulmonary phthalate levels due to inhalation expo-
sure. Secondly, the literature on phthalate-induced activation or modulation of PPARs is 
summarized. Based on these data, we discuss whether pulmonary phthalate exposure is likely 
to cause PPAR activation, and if this is a plausible mechanism for adverse effects of 
phthalates in the lung. It is concluded that the pulmonary concentrations of some phthalates 
may be sufficient to cause a direct activation of PPARs. Since PPARs mainly mediate anti-
inflammatory effects in the lungs, a direct activation is not a likely molecular mechanism for 
adverse effects of phthalates. However, possible modulatory effects of phthalates on PPARs 
deserve further investigation, including partial antagonist effects and/or cross talk with other 
signalling pathways. Moreover other mechanisms, including interactions between phthalates 
and other receptors, could also contribute to possible adverse pulmonary effects of phthalates. 
 
Keywords: Phthalates, asthma, Peroxisome Proliferation Activated Receptors, molecular 
mechanism 
 
 
 
INTRODUCTION 
During the last decades, the prevalence 
and incidence of respiratory allergies and 
asthma has reached extensive proportions 
especially in the industrialized countries. 
The airway symptoms may vary from mild 
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and temporary to severe and life threatening 
with urgent need for emergency treatment 
to restore normal breathing. Although the 
increase in prevalence appears to be level-
ling out and reaching a plateau in some 
countries, there is still a concern for this 
rise in prevalence in developing countries 
(Pearce and Douwes, 2006; Bousquet et al., 
2005; Lotvall et al., 2009). Moreover, the 
number of people affected by asthma is so 
high that it is considered as a major public 
health problem - especially for children -
 with global treatment costs running at bil-
lions of dollars each year (Bousquet et al., 
2005). A broad spectrum of factors seem to 
influence asthma development, ranging 
from genetics to life style and environmen-
tal factors, but much remains to be learned 
about what causes the disease and how to 
reduce its occurrence (Pearce and Douwes, 
2006; Bousquet et al., 2005). 
Since many children and infants spend 
more than 90 % of their time indoors 
(Leech et al., 2002), indoor factors are of 
particular interest with respect to environ-
mentally triggered conditions such as asth-
ma. Reviews have concluded that indoor 
factors like environmental tobacco smoke 
(Baena-Cagnani et al., 2009) as well as 
mold and dampness (Mendell et al., 2011) 
are associated with asthma development or 
exacerbations, although there is lack of 
knowledge concerning the underlying 
mechanisms. Moreover, a recent review 
concluded that more research was needed to 
clarify the potential risks related to chemi-
cals such as volatile and semi-volatile com-
pounds, phthalates and chlorinated chemi-
cals (Heinrich, 2011). However, several ep-
idemiological studies report an association 
between phthalate exposure and worsening 
or development of respiratory diseases, and 
a causal relationship has been suggested (as 
reviewed in (Bornehag and Nanberg, 2010; 
Jaakkola and Knight, 2008)). 
Phthalates are used as plasticisers in 
numerous consumer products, and since 
they are not covalently linked to the plastic, 
they leak out into the environment. Conse-
quently, phthalates are ubiquitous environ-
mental contaminants found in air, dust and 
food (Wormuth et al., 2006). The general 
population is continuously exposed to 
phthalates through inhalation, dermal up-
take and ingestion, as confirmed by the 
presence of phthalate metabolites in nearly 
all analysed urine samples in large popula-
tion based studies (Wittassek et al., 2011). 
When phthalates enter the human body they 
are rapidly hydrolysed to their primary me-
tabolites, and then further oxidized into var-
ious secondary metabolites (Wittassek et 
al., 2011). Generally, the low molecular 
weight phthalates (molecular weight < di-2-
ethylhexylphthalate; DEHP) are primarily 
metabolised into their monoesters, whereas 
the heavier phthalates (≥ DEHP) may be 
further metabolised into oxidative second-
ary metabolites. The phthalate metabolites 
are then secreted via urine. Although the 
metabolic pathways of phthalates after oral 
intake are partly known for some 
phthalates, the knowledge about distribu-
tion of metabolites in the body is limited 
(Frederiksen et al., 2007). When comparing 
the daily internal exposure to phthalates 
based on contribution of various sources, 
ingestion appears to be the major exposure 
route for many phthalates (Wormuth et al., 
2006). However, for diethylphthalate 
(DEP), di-n-butylphthalate (DnBP), bu-
tylbenzylphthalate (BBzP) and di-iso-
nonylphthalate (DiNP) inhalation exposure 
contributed to more than 20 % of the daily 
internal dose, suggesting that inhalation is 
an important exposure route for some 
phthalates (Wormuth et al., 2006). Interest-
ingly, fasting did not impact on the urinary 
levels of light weight phthalates, thus other 
pathways than ingestion appeared to con-
tribute to these levels (Wittassek et al., 
2011; Koch et al., 2013). Moreover, a sig-
nificant correlation has been reported be-
tween the metabolites of the low weight 
phthalates DEP, DnBP and BBzP in urine 
and the corresponding personal air levels 
(Adibi et al., 2003, 2008), and a recent 
study also reports a correlation between 
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BBzP	 in	dust	and	urinary	MBzP	 levels	 in	
children (Hsu et al., 2012). 
The levels of DEHP and BBzP in house 
dust have been associated with asthma and 
wheeze in children in a cross sectional 
study (Bornehag et al., 2004; Kolarik et al., 
2008), and BBzP was higher in house dust 
in homes of subjects categorised as allergic 
or asthmatic (Hsu et al., 2012). Both cross 
sectional and longitudinal studies show that 
use of polyvinyl chloride (PVC) flooring is 
related to asthma, and the correlations be-
tween PVC flooring and dust concentration 
of DEHP and BBzP, as well as uptake of 
BBzP in infants, provide further support for 
an association between phthalate exposure 
and asthma (Carlstedt et al., 2012). Urinary 
concentrations of the metabolites of DEP 
and DnBP were recently associated with 
decreased lung function in male volunteers 
(Hoppin et al., 2004), whereas the metabo-
lites of DEP and BBzP were associated 
with an increase in fractional exhaled nitric 
oxide, a marker of airway inflammation 
(Just et al., 2012). Moreover, the concentra-
tions of metabolites of the high molecular 
weight phthalates di-iso-decylphthalate 
(DiDP) and DiNP in urine were modestly 
associated with current asthma in children 
(Bertelsen et al., 2013), while the metabo-
lites of BBzP and DnBP were associated 
with diagnosed asthma (Hsu et al., 2012). 
Thus, there is emerging evidence for an as-
sociation between phthalate exposure and 
respiratory symptoms, although no firm link 
has been established between the inhalation 
exposure route and the various airway re-
sponses. 
Recent reviews of in vivo and in vitro 
studies of phthalates conclude that 
phthalates are capable of inducing an in-
flammatory response in lung and immune 
cells, and to modulate the response to a co-
allergen (Bornehag and Nanberg, 2010; 
Jaakkola and Knight, 2008). There is how-
ever still an ongoing discussion as to 
whether phthalates can induce inflammato-
ry and adjuvant responses at concentrations 
relevant for indoor air exposures (Larsen et 
al., 2007; Hansen et al., 2007; Nielsen et al., 
2007; Kimber and Dearman, 2010). Moreo-
ver, the molecular mechanisms involved in 
any inflammatory response to phthalates are 
largely unknown. Early studies on phthalate 
effects identified Peroxisome Proliferation 
Activated Receptors (PPAR)s as important 
targets for phthalates and possible media-
tors for various effects observed in the liver 
of some rodents (Rusyn et al., 2006; Hurst 
and Waxman, 2003). Thus, a similar mech-
anism with a phthalate-induced activation 
of PPARs has also been suggested in the 
pulmonary effects of phthalates (Magliozzi 
et al., 2003; Rosicarelli and Stefanini, 2009; 
Just et al., 2012). However, there are only 
few studies investigating if PPARs actually 
are involved in the phthalate-induced ef-
fects (Rakkestad et al., 2010; Bolling et al., 
2012; Larsen and Nielsen, 2007), these ei-
ther suggest an anti-inflammatory or modu-
latory role for PPARs (Rakkestad et al., 
2010; Bolling et al., 2012) or no influence 
on the phthalate-induced effects (Larsen 
and Nielsen, 2007). 
PPAR is a family of nuclear receptors 
that function as ligand-activated transcrip-
tion factors. They participate in a range of 
cellular processes including lipid metabo-
lism, glucose homeostasis, proliferation and 
differentiation, but also in positive and neg-
ative regulation of inflammation 
(Yessoufou and Wahli, 2010). The three 
known PPAR isotypes α, γ and δ/β can be 
activated by fatty acids, fatty acid deriva-
tives, but also by synthetic compounds like 
thiazolidinediones and phthalates 
(Yessoufou and Wahli, 2010). Upon activa-
tion by an appropriate ligand, PPARs form 
a heterodimer with RXRs (cis-retinoic acid 
receptors) and recruit nuclear co-activators 
or co-repressors before binding to specific 
promoter elements. In this way ligand bind-
ing to PPAR can result in both activation 
and inhibition of gene expression (Ricote 
and Glass, 2007). 
The three PPARs have unique though 
overlapping tissue distributions and func-
tions, but all PPARs are expressed in vari-
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ous cell types of the lung, including epithe-
lium, fibroblasts and smooth muscle cells, 
macrophages, T lymphocytes and eosino-
phils (Becker et al., 2006; Rehan et al., 
2009). As recently reviewed by Becker and 
co-authors, PPARs are mainly involved in 
anti-inflammatory responses in the lung, 
and they have been suggested as possible 
targets in the treatment of pulmonary symp-
toms in asthmatics (Becker et al., 2006). 
Similarly, PPAR agonists such as Rosiglita-
zone, are used as treatment for Type 2 dia-
betes, another disease with an inflammatory 
component (Gross and Staels, 2007). The 
involvement of PPARs in the development 
of inflammatory diseases like diabetes and 
asthma is not obvious, but phthalate-
induced dysregulation of PPARs has been 
proposed as a possible mechanism (Des-
vergne et al., 2009). 
In this review we discuss the likelihood 
of an involvement of PPAR in the exacer-
bation of asthma symptoms and the devel-
opment of asthma due to pulmonary expo-
sure to phthalates. First, we review the lit-
erature on indoor air levels for the most 
commonly measured phthalates, and sum-
marize the current knowledge on pulmo-
nary deposition, adsorption and metabolism 
of phthalates. These data are then used to 
estimate the pulmonary phthalate levels due 
to inhalation exposure. Secondly, the litera-
ture on phthalate-induced activation or 
modulation of PPARs is reviewed. Based 
on these data we discuss if PPAR activation 
is likely to be induced by pulmonary 
phthalate exposure and if PPAR activation 
is a plausible mechanism of action for 
phthalate induced effects in the lung. Final-
ly, other suggested mechanisms for 
phthalate-induced effects are briefly dis-
cussed. 
 
INHALATION EXPOSURE TO 
PHTHALATES 
Although ingestion and dermal uptake 
are believed to be the major exposure routes 
for most phthalates, exposure by inhalation 
is likely to cause a higher dose of phthalates 
in the lung than in other organs. This may 
be of importance for pulmonary endpoints 
like asthma and airway hyper responsive-
ness. In addition, exposure by inhalation 
may exclude first path metabolism/elimin-
ation of phthalates via the liver. 
Most phthalates fit to the definition of 
semi volatile organic compounds (SVOCs) 
and phthalates released from consumer 
products in indoor environments are present 
in the gas phase (Weschler et al., 2008). 
Like other SVOCs, the phthalates partition 
between gas phase, airborne particles, 
house dust and other surfaces. This parti-
tioning process depends on their individual 
vapour pressures, which is related to their 
molecular weights (Weschler and Nazaroff, 
2010). In general, phthalates with low mo-
lecular weight are predominately found in 
the gas phase whereas heavier phthalates 
are associated with particles (Weschler et 
al., 2008). For some of the high molecular 
weight phthalates, like DEHP, the partition-
ing between particle- and gas-phase is diffi-
cult to predict and depends on the physico-
chemical properties of the particles present 
in the indoor environment (Schossler et al., 
2011). 
 
Indoor air levels of phthalates 
Phthalate levels in indoor air are gener-
ally reported as the sum of the particulate 
and the semi-volatile fractions. In several 
epidemiological studies, phthalate levels in 
household dust (i.e. settled dust) have been 
used as a measure of phthalate exposure. 
These levels are more relevant for oral ex-
posure since children and especially infants 
are known to ingest considerable amounts 
of dust, thus they will not be discussed in 
detail here. Resuspension of settled dust 
might also contribute to indoor air levels; 
however, we assume that this resuspended 
dust is accounted for in the levels measured 
in indoor air. Note also that the phthalate 
adsorption to house dust particles differs 
from that to the airborne particles both with 
respect to the total amount of phthalates 
adsorbed and the relative amount of the var-
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ious types of phthalates. Generally, high 
molecular weight phthalates like DEHP are 
present in higher levels in house dust than 
in the gas and particle phase (Rudel et al., 
2003; Bergh et al., 2011; Fromme et al., 
2004). Moreover, the phthalate levels in the 
gas and particle phase cannot be calculated 
from the levels in house dust with sufficient 
accuracy (Weschler et al., 2008). 
Indoor air levels of phthalates have been 
reported for a range environments, includ-
ing homes, kindergartens, schools, universi-
ties, workplaces and cars (Rudel et al., 
2003; Fromme et al., 2004; Otake et al., 
2004; Rakkestad et al., 2007; Adibi et al., 
2003, 2008; Just et al., 2010; Bergh et al., 
2011; Kanazawa et al., 2010). Indoor air 
seems to be the major source for inhalation 
exposure to phthalates, since phthalate lev-
els in outdoor air are low, generally below 2 
ng/m3 (Otake et al., 2004; Rudel and 
Perovich, 2009). To summarize current data 
on indoor air levels of phthalates, the mean, 
median and range of levels reported in the 
nine identified studies are listed in Table 1a 
and 1b. The relative abundance of the dif-
ferent phthalates varies between the studies, 
but generally either DEP or DnBP are most 
abundant, with reported means in the ranges 
150-3000 ng/m3 and 100-2900 ng/m3, re-
spectively. Moreover DEHP and DiBP gen-
erally seem to be present in moderate lev-
els, with a range of mean concentrations of 
0-600 and 250-1000 ng/m3, respectively, 
whereas BBzP and DiNP are clearly the 
least abundant phthalates measured (Ta-
ble 1a and 1b). When the phthalate levels in 
homes, kindergartens and workplaces were 
compared, similar total levels and concen-
tration profiles for phthalates were found in 
the different environments (Bergh et al., 
2011). The reported mean values are often 
higher than the median (Table 1a and 1b), 
suggesting that the exposure distributions 
for phthalates are skewed due to much 
higher exposure levels for some individuals 
(Rudel et al., 2003). 
 
 
Table 1a and 1b: Phthalate concentrations in 
indoor air for (a) low and (b) high molecular 
weight phthalates. The levels represent the 
sum of vapour and particulate phases unless 
otherwise noted. The grey rows represent the 
range of reported values rounded to the nearest 
50. 
Table 1a Indoor air (ng/m3) 
Phthalate Mean Median Range/Max. 
DEP 150-3000 50-2700 0-7100 
Diethyl   590 a 130-4300 
phthalate 807 b 643 5481 
 396 c 353 1263 
 140 d 100 <10-610 
 1660 f  1380-2000** 
 2150 g  1920-2410** 
 1816 h  1668-1977** 
 1598 i 1300 680-3900 
 1246 j 870 650-2600 
 667 k 620 420-1400 
 3000 l 2700 1500-7100 
 1000 m 840 260-2900 
  61 n 22-203 
DnBP 100-2900 200-2300 0-15000 
Di-n-butyl   220 a 52-1100 
phthalate 1218 b 1083 5586 
 2395 c 1188 13305 
 750 d 390 <10-6180 
 75 e*  51-93 
 380 f  330-450** 
 450 g  410-510** 
 459 h  421-499** 
 925 i 850 300-2300 
 682 j 600 330-1700 
 599 k 550 190-1200 
 580 l 400 110-4100 
 2900 m 2300 750-15000 
  200 n 80-740 
DiBP 250-1000 50-800 0-8100 
Di-iso-
butyl  61
a 11-990 
phthalate 450 f  380-530** 
 500 g  440-570** 
 296 i 270 140-560 
 239 j 190 46-810 
 310 k 230 110-950 
 420 l 370 30-1300 
 1000 m 810 310-8100 
  75 n 13-321 
BBzP/BBP 0-100 0-50 0-650 
Butyl-
benzyl   < 31
a <31-480 
phthalate 37 b 18 575 
 -  c - 391 
 20 d 10 <1-110 
 10 e*  3-27 
 30 f  20-40** 
 50 g  40-60** 
 28 i  97 
 19 j  33 
 16 k  30 
 100 l 40 10-630 
 40 m 20 0-190 
  - n -27 
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Table 1b Indoor air (ng/m3) 
Phthalate Mean Median Range /Maximum 
DEHP 0-600 50-450 0-3150 
Di-2-
ethylhexyl   77 
a <59-1000  
phthalate 191 b 156 615 
 599 c 458 2253 
 320 d 110 <1-3130 
 12 e*  3-29 
 90 f  80-100 
 180 g   160-210 
 208 i 200 92-530 
 267 j 240 130-480 
 118 k 100 15-320 
 220 l 220 50-410 
 430 m 370 80-110 
  147 n 12-1660 
DiNP  0 0-200 
Di-iso-nonyl   - n -200 
phthalate    
* particle phase only  
** 95% CI 
a Rudel et al (2003); 101-120 homes 
b Fromme et al. (2004); 59 apartments  
c Fromme et al. (2004); 74 kindergartens 
d Otake et al. (2004); 27 homes  
e Rakkestad et al. (2007); 14 indoor environments 
(kindergartens, schools, universities, homes)  
f Adibi et al. (2008); 32 homes 
g Adibi et al. (2008); 48 hour personal air samples 
(n = 96) 
h Just et al. (2010); hour personal air samples 
(n = 186) 
I Bergh et al. (2011);10 homes 
j Bergh et al. (2011); 10 day care centres 
k Bergh et al. (2011): 10 workplaces 
l Adibi et al. (2003); 48 hour personal air samples 
(n = 30), New York 
m Adibi et al. (2003); 48 hour personal air samples 
(n = 30), Krakow, Poland 
n Kanazawa et al. (2010); 41 homes 
 
The use of DEHP has largely been 
phased out, but since DEHP was the most 
commonly used phthalate in PVC contain-
ing interior surface materials and consumer 
products for many decades, it may still be 
the most abundant phthalate in indoor dust 
samples, as long as these products are in 
use. Over the last ten years the use of 
phthalates with higher molecular weight has 
increased, but indoor concentrations for 
many of these phthalates have not been in-
vestigated (Schossler et al., 2011). For in-
stance DiNP and DiDP, that presently ac-
count for more than half of the overall plas-
ticizers consumption in Europe, have only 
been included in few studies of indoor dust 
(summarized in (Abb et al., 2009)), whereas 
only one study reports levels in the 
gas/particle phase for DiNP (Kanazawa et 
al., 2010). The reported mean values for 
DiNP and DiDP in house dust range from 
30-60 μg/g dust and 70-130 μg/g dust, re-
spectively. In comparison the mean values 
for DEHP seem to be considerably higher 
(750-2000 μg/g dust; (Fromme et al., 2004; 
Bergh et al., 2011)). Based on knowledge 
about the physical properties of high mo-
lecular weight phthalates, these compounds 
are likely to be present in the particle phase, 
yielding low gas phase concentrations 
(Schossler et al., 2011). 
 
THE FATE OF PHTHALATES  
IN THE LUNG 
The deposition pattern of gas and parti-
cle phase phthalates is likely to differ. Since 
low and high molecular weight phthalates 
partition differently between the gas and 
particle phase, it is necessary to distinguish 
between these phthalates when considering 
pulmonary phthalate exposure due to inha-
lation. 
 
Low molecular weight phthalates  
The lungs are covered by a thin layer of 
lung lining fluid (LLF) consisting of water, 
ions, proteins and antioxidants (Lewis, 
2006). The thickness of the layer varies be-
tween the different parts of the lungs, from 
6-10 µm in the upper part of the lungs to 
approximately 0.1 µm in the alveoli. Simi-
larly, the composition differs between the 
various parts of the lungs; with a high mu-
cous content in the conducting airways and 
a higher surfactant content in the alveoli 
(Ng et al., 2004). Calculations and meas-
urements based on volume markers suggest 
that the total volume of LLF in a human of 
70 kg is approximately 25 ml (Walters, 
2002). The LLF is covered by surfactant 
which consists of a monolayer of phospho-
lipids, neutral lipids and surfactant associat-
ed proteins (Lewis, 2006). Thus, inhaled 
phthalates are likely to first interact with the 
surfactant and then with the LLF. Low mo-
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lecular weight phthalates are primarily 
found in the gas phase, and the deposition 
of gas phase molecules will depend on 
physicochemical properties of the mole-
cules, such as the water solubility and mol-
ecule size. For instance, low water solubili-
ty of the molecules will result in higher 
deposition in the bronchiolar/alveolar re-
gions whereas high water solubility will 
result in higher deposition in the upper air-
ways (Bakand and Hayes, 2010). To our 
knowledge, pulmonary deposition of 
phthalates has not been elucidated, neither 
with regard to deposition site nor deposition 
probability. 
 
High molecular weight phthalates 
Since high molecular weight phthalates 
are primarily particle bound, the pulmonary 
dose and distribution of these phthalates 
will be determined by the physicochemical 
properties of the particulate matter they are 
adsorbed to (Phalen, 2002; Kreyling et al., 
2007; Löndahl et al., 2007). Particle deposi-
tion is highly non-uniform in the lung, and 
some sites receive much higher particle 
doses than others. In the peripheral lung, 
deposition of particulate matter is particu-
larly high in the proximal alveolar region, 
which is defined as the section located be-
tween the terminal bronchiole and the alve-
olar space (Donaldson et al., 2008; 
Pinkerton et al., 2004; Saldiva et al., 2002). 
The fate of particle bound phthalates af-
ter deposition in the lung has not been stud-
ied. However, partitioning between particle 
and aqueous phase has been studied in an 
environmental pollutant context for some 
phthalates and particle types (Julinova and 
Slavik, 2012; Xu and Li, 2008; Wang et al., 
2010). Since adsorption/desorption of 
phthalates from particles is an equilibrium 
process it is likely that phthalates desorb 
into the LLF to some extent after deposi-
tion. The degree of desorption depends on 
the properties of the particulate matter and 
the LLF, as well as the mass to volume ra-
tio. Experimental studies are necessary to 
address desorption of phthalates in the con-
text of inhaled particulate matter. 
 
Pulmonary phthalate kinetics 
Many studies have used DEHP as a 
model compound to investigate the absorp-
tion, distribution and metabolism as well as 
toxicity of phthalates. Based on data from 
human and animal studies, metabolism of 
DEHP has been shown to involve a com-
plex series of reactions that produce a high 
number of metabolites, including mono-2-
ethylhexylphthalate (MEHP) (Koch et al., 
2006). 
Generally, phthalates are rapidly me-
tabolised after absorption through a lipase 
mediated cleavage into hydrolytic monoes-
ters, followed by oxidation of the alkyl 
chain of the monoesters causing formation 
of various secondary metabolites (Koch and 
Calafat, 2009). The low molecular weight 
phthalates are mostly metabolised into their 
monoesters, whereas the heavier phthalates 
may be further metabolised into oxidative 
secondary metabolites (Koch and Calafat, 
2009). The lipases that mediate the hydro-
lytic cleavage of phthalates have been iden-
tified in a number of organs including 
lungs, where they have been found in sev-
eral cell types such as alveolar macrophages 
and type 2 cells as well as in LLF (Albro 
and Thomas, 1973; Mahoney et al., 1982; 
Coonrod et al., 1989). This suggests that 
pulmonary hydrolysis of phthalates, with 
subsequent cellular exposure to phthalate 
monoesters, is possible. However, it is 
presently not known to what extent 
phthalate metabolism takes place in the 
lung (Albro and Thomas, 1973; Mahoney et 
al., 1982; Coonrod et al., 1989). Although 
the lipase activity as well as the metabolic 
rate in lung tissue has been shown to be 
lower compared to intestines, liver and kid-
ney (Ito et al., 2005; Choi et al., 2012), this 
does not exclude the possibility that 
phthalates might be metabolised in the lung 
after inhalation exposure. 
A recent review of DEHP toxicity con-
ducted by United States Consumer Product 
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Safety Commission concluded that absorp-
tion of DEHP after inhalation exposure has 
received limited investigations both in hu-
mans as well as rodents. Thus the kinetics 
of human phthalate metabolism after inha-
lation exposure and the site for the hydroly-
sis of phthalates into secondary metabolites 
is largely unknown. However, DEHP has 
been reported to translocate rapidly from 
the lung to the blood stream in rodents, 
suggesting only transient exposure of pul-
monary cells (Carlson, 2010). Although this 
might suggest rapid absorption and distribu-
tion also in the humans, it remains to be 
elucidated whether the absorption is slow 
enough to allow for pulmonary metabolism 
of phthalates. Interestingly, the metabolism 
of inhaled DEHP to MEHP in rodent lung 
has been suggested to be in the order of 1-
3 % based on comparison of the doses of 
DEHP and MEHP inducing similar effects 
on airway irritation, airway inflammation 
and allergen specific IgE production in 
mice (Larsen et al., 2007). 
 
ESTIMATES OF PULMONARY 
PHTHALATE LEVELS  
Indoor phthalate levels have been used 
to calculate the inhalation exposure and 
then estimate the relative contribution of 
inhalation exposure to the total phthalate 
exposure (Otake et al., 2004; Fromme et al., 
2004). Inhalation exposure to DEHP, DEP 
and BBzP was estimated to account for ap-
proximately 1-2 % of the total exposure, 
whereas inhalation of DnBP may contribute 
with up to 20 % of the total exposure 
(Otake et al., 2004; Fromme et al., 2004). 
Thus, inhalation exposure seems to account 
for a small part of the total body burden of 
phthalates. However, estimates of pulmo-
nary phthalate concentrations due to inhala-
tion exposure have to our knowledge not 
been reported previously.  
The calculations of daily inhalation 
doses done by Otake and Fromme and their 
co-authors assumed that all the inhaled 
phthalates remained in the lung. However, 
since phthalates are relatively small mole-
cules, they may be likely to follow the ex-
piratory air flow to a certain extent. Such 
daily inhalation doses must therefore be 
considered as the maximum possible expo-
sure dose. To obtain a rough estimate of the 
pulmonary phthalate levels due to inhala-
tion exposure we estimate the phthalate lev-
els in the LLF based on the exposure esti-
mated from the indoor air concentrations. 
Due to limited knowledge on pulmonary 
phthalate deposition, we assume in our cal-
culations that both particle and vapour 
phase phthalates deposit evenly in the LLF, 
although an uneven distribution is probably 
more likely both for gas and particle phase 
phthalates. Moreover, we assume that all 
the inhaled phthalates remain in the lung, as 
in the previous calculations by Otake and 
Fromme and their co-authors. Since the 
clearance kinetics of phthalates from the 
lungs is not well known, we have chosen to 
calculate the amount of deposited phthalate 
after both 2 and 24 hours inhalation, repre-
senting rapid and slow absorption respec-
tively. The reported phthalate concentra-
tions summarized in Table 1a and 1b exhib-
it great variation, we therefore present cal-
culations for the lowest and highest report-
ed mean values, as well as for the maxi-
mum reported levels, for each phthalate 
(Table 2). 
The calculations were done for adults 
(20-70 years) and children (0-4 years) as-
suming inhalation volumes for 24 hours of 
23 and 5 m3 respectively (Fromme et al., 
2004). For the volume of LLF estimates of 
25 ml was used for an adult of 70 kg and 
5,6 ml for a child of 16 kg (Walters, 2002). 
The total amount of inhaled phthalate was 
calculated (phthalate concentration * in-
haled volume; not shown), and the corre-
sponding phthalate concentration in the 
LLF was calculated (amount of inhaled 
phthalate / volume of LLF) to determine the 
molar concentration presented in Table 2. 
The estimated pulmonary levels for adults 
and children are almost identical since the 
inhalation volume to LLF volume ratio is 
almost equal for the two cases, 23/25 = 0.92 
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for adults and 5/5.6 = 0.89 for children. We 
have therefore chosen to show only the data 
for children (Table 2).  
 
 
Table 2: Rough estimates of pulmonary 
phthalate concentrations due to inhalation ex-
posure. The table shows the maximum levels 
reported for each phthalate as well as the high-
est and lowest mean values, for each phthalate, 
and the corresponding calculated concentra-
tions of phthalates in LLF after 2 or 24 hours 
inhalation. See main text for assumptions and 
explanation of calculations. 
Phtha-
late 
Indoor air  
concentration 
(from Table 1) 
Rough estimate for 
phthalate concentration 
in LLF 
 (μg/m3)  (μM) 
  2 hours  
inhalation 
24 hours 
inhalation 
DEP Max 7.1   2.4 28.5 
 
high 
mean 2.2   0.7 8.6 
low 
mean 0.2   0.1 0.6 
DnBP Max 15.0   4.0 48.1 
 
high 
mean 2.9   0.8 9.3 
 
low 
mean 0.1   0.03 0.3 
DiBP Max 8.1   2.2 26.0 
 
high 
mean 1.0   0.3 3.2 
low 
mean 0.3   0.1 0.8 
BBzP Max 0.7   0.2 1.9 
 
high 
mean 0.1   0.02 0.3 
low 
mean 0.01   0.002 0.03 
DEHP Max 3.2   0.6 7.2 
 
high 
mean 0.6   0.1 1.4 
  
low 
mean 0.01   0.002 0.02 
DiNP Max 0.2   0.04 0.4 
 
The rough estimates presented in Ta-
ble 2 should be interpreted cautiously since 
they are based on multiple assumptions and 
are highly uncertain. Nevertheless they pro-
vide tentative concentration ranges for pul-
monary phthalate concentrations due to in-
halation exposure. If a rapid absorption of 
phthalates is assumed, the maximal and 
high mean indoor air levels will correspond 
to estimated pulmonary concentrations of 
0.04 - 4 µM and 0.02 - 0.8 µM, respectively 
(Table 2). For a slow absorption, the corre-
sponding concentrations are 0.4 - 48.1 µM 
and 0.3 - 9.3 µM. Keep in mind that the 
phthalate levels represent maximum deposi-
tion, i.e. all inhaled phthalates are assumed 
to deposit in the lung, suggesting that the 
estimates are higher than the actual expo-
sure. In addition, a uniform pulmonary dep-
osition was assumed, whereas a more likely 
scenario would be a non-uniform distribu-
tion with higher concentrations in some re-
gions of the lung and lower in others. 
 
PHTHALATES AS PPAR-LIGANDS 
AND -GENE MODULA-
TORS/ACTIVATORS 
Early rodent studies of phthalate in-
duced effects suggested PPARs as im-
portant targets for phthalates, and PPARs 
have also been suggested to play a role in 
the pulmonary effects of phthalates 
(Magliozzi et al., 2003; Rosicarelli and 
Stefanini, 2009). PPARs are involved in a 
wide range of biological processes, and are 
expressed in immune and lung cells in-
volved in asthma development and exacer-
bation (Becker et al., 2006; Di Paola and 
Cuzzocrea, 2007). Several aspects of the 
interaction between phthalates and the three 
PPAR isotypes (α, γ and δ/β) have been 
studied, including molecular modelling of 
phthalate-PPAR interaction and co-variator 
recruitment in cell free assays (see chapter 
PPAR-ligand binding and activation in 
cell free systems), trans-activation studies 
using transfected cells and activation of 
constitutive PPAR in cellular models (see 
chapter PPAR trans-activation studies). 
In addition, a limited number of studies 
have investigated other modes of action for 
phthalates, including inhibitory and modu-
lating effects (see chapter Inhibitory or 
modulating effects of phthalates on 
PPAR activity). 
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PPAR-LIGAND BINDING AND ACTI-
VATION IN CELL FREE SYSTEMS 
The ligand binding domains (LBD) of 
PPARs are well characterized, thus receptor 
binding of phthalates can now be studied 
not only in “classic” competitive receptor 
binding studies, but also by computer based 
modelling. These studies are based on cal-
culations of the binding energies between 
the LBD of the PPAR and knowledge of the 
molecular structure of the respective 
phthalates (Nakagawa et al., 2008; Kambia 
et al., 2008; Kaya et al., 2006; Feige et al., 
2007). They have revealed that the primary 
metabolites of phthalates (hydrolysed com-
pounds) are more likely PPAR ligands than 
the parent compounds and the secondary 
metabolites (oxidised phthalates). For in-
stance, computational studies suggest that 
MEHP can bind to PPARα and γ, whereas 
the parent compound DEHP is unable to 
bind or exhibits weak binding (Feige et al., 
2007; Kambia et al., 2008). Similarly, in a 
co-variator recruitment study, MEHP in-
duced a dose dependent increase in PPARγ 
activity, whereas DEHP and the oxidised 
metabolites showed no activation (Kusu et 
al., 2008). 
When a wider range of phthalate me-
tabolites was investigated, the ability of 
phthalates to bind to PPARs differed con-
siderably between the various phthalates, 
and their molecular structure affected the 
strength of the bond (Nakagawa et al., 
2008; Kaya et al., 2006). The calculated 
free energies from a computational screen-
ing for binding of phthalate monoesters to 
PPARγ correlated well (R2 = 0.82) with the 
log EC50 values determined in an in vitro 
trans-activation study (Kaya et al., 2006; 
Lampen et al., 2003), suggesting that data 
from molecular modelling could be used to 
identify possible PPAR ligands (Kaya et al., 
2006). EC50 denotes an equivalent concen-
tration resulting in 50 % of the maximum 
response level. Based on these correlations 
Kaya and co-authors identified 20 new 
phthalate monoesters that were ranked as 
potent PPARγ activators. Thus, a high 
number of phthalates, many of which have 
not yet been included in environmental ex-
posure studies, could potentially activate 
PPARs. Although the correlation between 
calculations and in vitro data strengthens 
the reliability of data from molecular mod-
elling, it is necessary to verify such findings 
in experimental model systems (Kaya et al., 
2006). 
 
PPAR TRANS-ACTIVATION STUDIES 
In accordance with the molecular mod-
elling studies, cell transfection studies re-
port that both mouse and human PPARα 
and PPARγ were activated by MEHP, but 
not by the parent compound DEHP 
(Maloney and Waxman, 1999; Lapinskas et 
al., 2005). In contrast, BBzP and DnBP 
were able to activate all three PPAR sub-
types, and to a slightly higher extent than 
their metabolite mono-n-butylphthalate 
(MnBP) (Lapinskas et al., 2005). Thus, 
some of the parent phthalates may activate 
PPARs directly, rather than through their 
primary metabolites. 
 
Phthalate metabolites 
A range of different cell lines have been 
applied in transfection studies using differ-
ent PPAR isotypes, mouse or human, or in 
some cases both, in order to compare spe-
cies sensitivity. A similar degree of activa-
tion for human and mouse PPARα was re-
ported by Lampen and co-authors, whereas 
two other studies reported that mouse 
PPARα was activated at lower concentra-
tions than human PPARα (Hurst and 
Waxman, 2003; Bility et al., 2004; Lampen 
et al., 2003). In contrast, mouse and human 
PPARγ were trans-activated at similar con-
centrations by a range of phthalate monoes-
ters (Lampen et al., 2003; Bility et al., 
2004; Hurst and Waxman, 2003). A study 
comparing species sensitivity for PPARδ/β 
reported that mouse PPARδ/β was activated 
by several phthalate monoesters while hu-
man PPARδ/β was inactive (Bility et al., 
2004). Thus, the data concerning the affini-
ty of human versus mouse PPAR for bind-
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ing to phthalates is somewhat conflicting. It 
is, however, important to remember that the 
phthalate responses obtained also may de-
pend on the specific cell type used. Feige 
and co-workers compared the ability of 
MEHP to activate PPARγ in different cell 
types and reported that the affinity (i.e. the 
concentration where the effect occurred) 
was rather similar for all cell types, while 
the efficacy (i.e. the maximal level of acti-
vation) seemed to vary (Feige et al., 2007).  
When comparing the sensitivity of the 
three PPAR isotypes α, γ and δ/β Lampen 
and co-authors (2003) found that most of 
the investigated phthalate monoesters had a 
higher affinity (i.e. lower EC50) for PPARγ 
than PPARα. In contrast, a more recent 
study using MEHP as a model compound, 
reported a similar affinity for PPARα and γ, 
although the efficacy of MEHP was higher 
for PPARγ than the α-form (Feige et al., 
2007). 
A number of in vitro studies report dif-
ferential PPAR activation for the various 
phthalate monoesters, and the range of the 
lowest activation concentrations and the 
maximum fold increase are given in Ta-
ble 3. A direct comparison of the different 
studies is difficult since different measures 
of PPAR activation have been used; some 
studies report EC50 values, while others re-
port the lowest concentration causing sig-
nificant response (EClow). Thus, both these 
measures are included in Supplementary 
material to allow for inclusion of data from 
all available studies. As seen in Table 3 
there is a large span in the ability of the var-
ious phthalates to activate PPARs. The 
lowest activation concentrations range from 
0.1-300 μM, with maximal fold inductions 
from 2-32. Generally, the metabolites from 
low molecular weight phthalates (< MEHP) 
show no PPAR activation, or only activa-
tion at moderate to high concentrations. On 
the other hand, metabolites from phthalate 
monoesters with higher molecular weight 
(≥ MEHP) generally cause activation of 
PPARs in transfection studies, with the ex-
ception of human PPARδ/β. Accordingly, 
the potency and efficacy of phthalate mo-
noesters to activate PPARα and PPARγ has 
been reported to increase with increasing 
side chain length (Lampen et al., 2003; 
Bility et al., 2004), suggesting that high mo-
lecular weight phthalates are more potent 
PPAR ligands than low molecular weight 
phthalates. For PPARδ/β however, the low-
est activation concentrations are in the same 
range both for low and high molecular 
weight phthalates. 
Some of these studies compared the ef-
ficacy of the phthalates to induce PPAR 
activation to that of known PPAR agonists 
like Rosiglitazone, Troglitazone and 
Wy14643. Regarding MEHP, two studies 
reported that the efficacy was lower than 
that of the PPAR agonists used as positive 
controls (Lapinskas et al., 2005; Maloney 
and Waxman, 1999). In contrast, a third 
study reported that MEHP could have a 
similar efficacy as the known PPAR ago-
nists, but that the efficacy depended on 
PPAR isotype, species (human vs. mouse) 
and applied cell type (Feige et al., 2007). 
Bility and co-authors compared the efficacy 
of a range of different phthalate metabolites 
to positive controls, and found that metabo-
lites of the high molecular weight 
phthalates generally gave a similar or high-
er maximum fold increase as the positive 
control for PPARα and γ (Bility et al., 
2004). Thus, the efficacy of phthalate me-
tabolites to activate PPARs may be lower 
than the efficacy of known PPAR agonists, 
but many of the high molecular weight 
phthalates appear to be able to act as full 
agonists. Combined exposure to phthalates 
and other PPAR agonists were rarely con-
ducted (Gopisetty Venkata et al., 2006). 
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Table 3: Phthlate-induced activation of PPARs in transfection studies. Summary of the lowest activa-
tion range and the maximum fold increase in PPAR activation reported in the literature (Hurst and 
Waxman, 2003; Maloney and Waxman, 1999; Lampen et al., 2003; Gopisetty Venkata et al., 2006; 
Feige et al., 2007; Lapinskas et al., 2005; Bility et al., 2004), with the full data provided in Supplemen-
tary material. The dotted line represents the division between metabolites originating from low and 
high molecular weight phthalates. 
 
PPARα   
 human PPARα mouse PPARα 
Phthalate  
monoester 
Lowest activation  
concentration (μM) 
Maximum 
fold increase 
Lowest activation 
concentration (μM) 
Maximum 
fold increase 
     
MMP No act.  No act.  
MEP No act.  No act.  
MsecBP No act.  10 1.5-3 
MnBP 10-200 0.5-2 100 4 
MBzP 30-300 2-3 10-100 2-12 
MEHP 3-100 2-4 0.5-40 2-7 
MnOP 10 8 10 32 
MiNP 10 6 3 27 
MiDP 30 4 3 27 
PPARγ   
 human PPARγ mouse PPARγ 
Phthalate  
monoester 
Lowest activation  
concentration (μM) 
Maximum 
fold increase 
Lowest activation  
concentration (μM) 
Maximum 
fold increase 
MMP No act.  No act.  
MEP No act.  No act.  
MsecBP No act.  300 2 
MnBP No act.  No act.  
MBzP 30-200 2-4 10-100 2-8 
MEHP 0.1-10 1.5-10 3-30 1.5-7 
MnOP 100 19 10 11 
MiNP 30 9 3 14 
MiDP 3 8 30 4 
PPARδ/β   
 human PPARδ/β mouse PPARδ/β 
Phthalate  
monoester 
Lowest activation  
concentration (μM) 
Maximum 
fold increase 
Lowest activation  
concentration (μM) 
Maximum 
fold increase 
MMP No act.  No act.  
MEP No act.  No act.  
MnBP No act.  0.1-3 0.5-5 
MBzP No act.  100 11 
MEHP 60 3-6 0.1-200 0.6-17 
MnOP No act.  100 13 
MiNP No act.   3 
MiDP No act.  100 8 
Abbreviations: monomethylphthalate (MMP), monoethylphthalate (MEP), mono-sec-butylphthalate 
(MsecBP), mono-n-butylphthalate (MnBP), monobenzylphthalate (MBzP), mono-2-ethylhexylphthalate 
(MEHP), mono-n-octylphthalate (MnOP), monoisononylphthalate (MiNP), monoisodecylphthalate 
(MiDP) 
 
 
Parent phthalates  
Although the light molecular weight 
phthalates DnBP and BBzP have been re-
ported to be able to bind and activate 
PPARs, several of the transfection studies 
have only included the metabolites of these 
phthalates rather than the parent phthalates 
(Gopisetty Venkata et al., 2006; Hurst and 
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Waxman, 2003; Bility et al., 2004). Both 
DnBP and BBzP caused a significant in-
crease in luciferase activity for all three 
PPAR isotypes, but the efficacy was con-
siderably lower than for MEHP (Lapinskas 
et al., 2005). Accordingly, Lampen and co-
authors also reported that BBzP could inter-
act with all three PPAR isotypes, with EC2x 
values of 60, 125 and 175 µM for PPARα, γ 
and δ/β, respectively, where EC2x is defined 
as the concentration that induced a reporter 
gene response twice as high as the control 
(Lampen et al., 2003). Since neither of 
these two papers provided a measure of 
lowest activation concentration or maxi-
mum fold increase, DnBP and BBzP are not 
included in Table 3. Interestingly, La-
pinskas et al. (2005) also reported that both 
these low weight phthalates could bind to 
hPPARs, with lowest binding concentra-
tions for DnBP and BBzP of 34 and 27 µM 
for PPARα and 10 and 10 µM for PPARγ, 
respectively. As a reference, the lowest 
binding concentrations for MEHP were 15 
and 12 µM for PPARα and γ. Thus, DnBP 
and BBzP might bind and activate PPARs 
at relatively low concentrations, although 
their efficacy may be low compared to 
MEHP and other known PPAR agonists. 
Moreover, the parent phthalates appear to 
be more likely PPAR ligands than their 
primary metabolites for these low molecu-
lar weight phthalates. 
 
Activation of endogeneous PPARs 
Activation of endogenous PPARs in 
cellular models where PPAR is naturally 
present rather than transfected, has been 
studied for PPARα and γ in either in vitro 
or in vivo model systems, in relation to ef-
fects in liver and adipose tissue. Thus, the 
investigated cell types or organs are of lim-
ited relevance for the lung. For the liver, 
relatively high concentrations of both 
DEHP and DEP increased expression of 
lipid metabolizing enzymes in the liver of 
wild-type mice, while no response could be 
seen in PPARα-null mice (Lapinskas et al., 
2005). Moreover, activation of constitutive 
PPARα by phthalate monoesters was ob-
served in a rat liver cell line as increased 
transcription of endogenous genes, but at 
slightly higher concentrations than in a lu-
ciferace transfection assay. However, no 
phthalate monoesters activated PPARα tar-
get genes in a human liver cell line (Bility 
et al., 2004). With respect to adipose tissue, 
differentiation of 3T3-L1 fibroblasts into 
adipocytes has been found to depend on 
PPARγ, and this model is thus frequently 
used to investigate activation of constitutive 
PPARγ on endogenous genes (Bility et al., 
2004; Hurst and Waxman, 2003; Feige et 
al., 2007). MEHP promoted adipogenesis in 
a PPARγ dependent manner at concentra-
tions between 10 and 100 µM in this model 
system, with a sensitivity and efficacy simi-
lar to that reported in various luciferase re-
porter systems (Feige et al., 2007; Bility et 
al., 2004). 
 
Summary 
Phthalates have been demonstrated to 
bind and activate PPARs, although the po-
tency varies between the different 
phthalates, and the activation depends on 
the isoform, species and cell model used. 
Generally, the primary metabolites i.e. the 
phthalate monoesters are the most potent 
PPAR agonists. However, for some of the 
low molecular weight phthalates the parent 
compounds have been reported to be more 
potent than their primary metabolites. 
PPARα and γ seem to have a similar sensi-
tivity to activation by phthalate monoesters, 
whereas PPARδ/β has a lower sensitivity to 
some monoesters. Using transfection as-
says, the difference between mouse and 
man is most evident for PPARα; and inter-
estingly a similar difference in species sen-
sitivity was also reported for endogenous 
model systems. However, activation of en-
dogenous PPARγ by phthalates has not 
been tested in a model system of human 
origin, thus further research is necessary to 
elucidate this issue. 
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INHIBITORY OR MODULATING 
EFFECTS OF PHTHALATES ON 
PPAR ACTIVITY 
As summarized in the previous chapter, 
a range of studies show that phthalates can 
bind and activate PPARs resulting in an ag-
onistic effect. With respect to inhibitory 
effects, MnBP was reported to reduce the 
PPARα activation in a luciferase assay, 
suggesting an antagonistic effect of MnBP 
(Gopisetty Venkata et al., 2006). Based on 
combined exposure to MnBP and known 
PPAR agonists, the same study suggested 
that MnBP is an antagonist for PPARγ and 
a weak antagonist for PPARδ/β (Gopisetty 
Venkata et al., 2006). To our knowledge, no 
other studies report antagonistic effects of 
phthalates in PPAR transfection studies. 
However, MnBP, DnBP and MEHP were 
reported to have antagonistic effects with 
regard to co-variator recruitment by 
PPARγ, whereas only the DnBP metabolite 
DnBP-4OH had antagonistic effects on co-
variator recruitment by PPARα (Kusu et al., 
2008). Another possibility for inhibitory 
effects of phthalates on PPARs is that 
phthalates could display an indirect inhibi-
tory effect, by acting as partial agonists, i.e. 
by causing lower activity at saturating con-
centrations than the activity of a full agonist 
(Zhu, 2005). Interestingly, for some 
phthalates and in some cell types, the effi-
cacy of phthalate metabolites to activate 
PPARs appears to be lower than the effica-
cy of known PPAR agonists (see chapter 
PPAR trans-activation studies), indicating 
a sub-optimal activation of PPARs by 
phthalates. However, possible implications 
of partial agonist effects of phthalates on 
PPAR activation have not been extensively 
studied. 
The concept of ‘selective nuclear recep-
tor modulators’, i.e., that a modulating lig-
and can induce a specific conformational 
change of the receptor followed by recruit-
ment of only a subset of co-regulators, 
emerged from studies on the tissue-specific 
modulation of the estrogen receptor (Shang 
and Brown, 2002). Since the promoters of 
target genes have specific requirements to 
regulate transcriptional activation this will 
induce activation of only a selection of tar-
get genes (Shang and Brown, 2002). For 
phthalates and PPARs, Feige and co-
authors demonstrated that MEHP and the 
synthetic PPAR ligand Rosiglitazone acti-
vated different subsets of genes in adipo-
cyte differentiation, a process known to de-
pend on PPARγ (Feige et al., 2007). The 
selective activity correlated with the re-
cruitment of a specific subset of PPARγ co-
regulators. The authors suggested that this 
weak dysregulation could cause small 
changes in regulatory pathways that are not 
easily detected and might not be evident as 
clinical effects/symptoms before after an 
extended period of time. However, the 
phthalate-induced gene activation has not 
yet been compared to the activation induced 
by endogenous PPAR ligands.  
One study investigated if phthalates 
could influence the effects of the endoge-
nous PPARγ ligand 15d-PGJ2 in B-cells, 
representing another possible modulatory 
mode of phthalates (Schlezinger et al., 
2004). MEHP induced an additive decrease 
in the proliferation and increase in the 
apoptosis induced by 15d-PGJ2 in B-cell 
lines at MEHP concentrations between 25 
and 100 µM, whereas similar effects were 
observed at lower concentrations (10–
15 µM) in primary B-cells. The 15d-PGJ2 
levels applied by Schlezinger and co-
authors were reported to be relevant for the 
levels in the bone marrow micro-environ-
ment, but not for the estimated pulmonary 
levels. Thus the study has limited relevance 
for the pulmonary situation except for 
demonstrating a possible modulatory mode 
of action for phthalates on PPAR activation.  
Interestingly, MEHP induced activation 
of PPARα and γ has been found to cause 
inhibition of the transcription factor STAT5 
at much lower concentrations than those 
required for a more “classic” direct PPAR 
activation (Shipley and Waxman, 2004). 
For inhibition of STAT5, in kidney fibro-
blast cells, the EC50 value was as low as 
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1.1 µM, whereas the corresponding value 
for PPAR activation was 10 µM. STAT5 is 
involved in several immune processes, in-
cluding proliferation, survival, and release 
of inflammatory mediators in mast cells, 
development and maintenance of T regula-
tory (Treg) cells, negative regulation of T 
helper 17 (Th17) cell differentiation, and 
possibly differentiation into M2 macro-
phages (Morales et al., 2010; Wei et al., 
2008; Pullen et al., 2012; Xiao et al., 2008). 
Thus an inhibition of STAT5 due to 
phthalate-induced PPAR effects might also 
have relevance for the lung. Moreover, the 
crosstalk with other signalling pathways 
due to phthalate-induced PPAR activation 
reported by Shipley and Waxman (2004) 
occurred at much lower concentrations than 
those required for direct PPAR activation, 
and represents a mode of action for 
phthalates that could be relevant for other 
cell types, and possibly also other signalling 
pathways. 
 
ARE THE PULMONARY 
PHTHALATE CONCENTRATIONS 
SUFFICIENT TO ACTIVATE HUMAN 
PPARS? 
Human PPARs seem to be activated on-
ly by a selection of phthalate metabolites 
(Table 3), and predominantly by the metab-
olites of the high molecular weight 
phthalates like DEHP, DiNP and DiDP. 
Generally, concentrations sufficient for 
PPAR activation in Table 3 appear to be 
highest for the low weight phthalates, sug-
gesting that a higher concentration of their 
metabolites is necessary for a “classic” 
PPAR activation. Although the inhalation 
exposure (Table 1a and 1b) and the estimat-
ed pulmonary phthalate concentrations (Ta-
ble 2) appear to be higher for the low 
weight phthalates, it is not obvious that the 
concentrations of phthalates that are able to 
activate PPARs will be reached by inhala-
tion exposure only.  
In order to discuss whether the pulmo-
nary phthalate concentrations due to inhala-
tion exposure are likely to activate human 
PPARs, we will compare the lowest activa-
tion concentrations presented in Table 3 to 
the maximal estimated pulmonary phthalate 
levels in Table 2. Since the rate of phthalate 
metabolism in the lung is not known we 
look at two highly diverging scenarios (i) 
1 % metabolite formation as suggested by 
Larsen et al (2007) representative of low 
pulmonary metabolism and (ii) 50 % me-
tabolite formation representative for a high 
pulmonary phthalate metabolism (Table 4). 
Comparison of the estimated metabolite 
levels and the lowest activation concentra-
tions for PPARs, assuming 1 % metabolic 
rate, suggests that PPAR activation is not 
likely due to inhalation exposure. Assuming 
50 % metabolic rate, activation of PPARα 
and γ may be possible for individuals high-
ly exposed to DEHP, while PPARα activa-
tion may occur in individuals highly ex-
posed to DnBP. Remember though that the 
maximal pulmonary metabolite levels in 
Table 4 represent maximum exposure, max-
imum deposition, minimal absorption to the 
blood and maximal pulmonary metabolism. 
Since the parent phthalates DnBP and 
BBzP have also been reported to bind and 
activate PPARs (Lampen et al., 2003; 
Lapinskas et al., 2005), a scenario involving 
a direct interaction between these phthalates 
and the three PPAR isotypes should also be 
considered. No measure of lowest activa-
tion concentration has been reported in the 
literature. However, the estimated pulmo-
nary phthalate concentrations in the first 
column of Table 4 may be compared to the 
lowest binding concentrations for DnBP 
and BBzP of 34 and 27 µM for hPPARα 
and 10 and 10 µM for hPPARγ, respective-
ly (Lapinskas et al., 2005). For DnBP, but 
not BBzP, the estimated pulmonary concen-
tration exceeds the lowest binding concen-
trations, suggesting that a direct activation 
of PPARα and γ is more likely for DnBP 
than BBzP. Further studies are however 
necessary to study PPAR activation due to 
DnBP binding and determine the lowest 
activation concentration. 
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Table 4: Comparison of maximal estimated metabolite levels and lowest activation concentrations. 
The table compares the lowest activation concentrations presented in Table 3 to the maximal estimat-
ed pulmonary phthalate levels in Table 2. Two different metabolic rates (met. rate) are included since 
the rate of phthalate metabolism in the lung is not known, see main text for detailed description. 
Rough estimates of maximum pulmonary  
concentrations (μM) Lowest activation concentrations for hPPARs (μM)
Phthalates* Metabolites  
    1 % met. rate 
50 % 
met. rate
 
PPARα 
 
 
PPARγ 
 
 
PPAR δ/β 
 
DnBP 48.1  MnBP 0.5 24.1 10-200 No act. No act. 
BBzP 1.9  MBzP 0.02 0.9 30-300 30-200 No act. 
DEHP 7.2  MEHP 0.07 3.6 3-100 0.1-10 60 
DiNP 0.4  MiNP 0.004 0.2 10 30 No act. 
*DEP and DMP were not included due to lack of PPAR activation and DsecBP, DnOP and DiDP were 
not included due to lack of indoor air levels, while DiBP was excluded due to lack of PPAR activation 
data. 
 
 
Although the metabolites of the high 
molecular weight phthalates generally ap-
pear to be more potent than the low molecu-
lar weight phthalates, the information re-
garding the levels of these phthalates in in-
door air is scarce. We could only identify 
one study reporting data for DiNP, and 
based on these data the estimated pulmo-
nary metabolite levels were 50 times lower 
than the lowest reported PPAR activation 
concentration, even when assuming 50 % 
metabolic rate. Thus, a direct activation of 
PPARs does not appear to be likely. Keep 
in mind though, that high weight phthalates 
like DiNP and DiDP are likely to partition 
to the particle phase rather than the gas 
phase (Schossler et al., 2011), suggesting 
uneven pulmonary deposition and higher 
concentrations of particles and thus 
phthalates in some regions than others (see 
chapter The fate of phthalates in the 
lung). 
 
PPARS IN ASTHMA DEVELOPMENT 
AND EXACERBATION 
Asthma is a heterogeneous and complex 
disease caused by multiple factors (Kim et 
al., 2010), with genetic predispositions and 
environmental exposures in early life as the 
major identified risk factors for asthma de-
velopment (Sly, 2011). There are several 
phenotypes of asthma, including allergic, 
non-allergic and intrinsic asthma, and the 
cellular and molecular pathways involved 
in the development and pathogenesis of 
these different asthma phenotypes differs 
(Kim et al., 2010). In allergic asthma, anti-
gen presenting cells like dendritic cells in-
duce antigen-specific responses in T helper 
type 2 (TH2) cells, resulting in IgE produc-
tion and sensitisation of basophils and mast 
cells. Basophils, eosinophils, mast cells and 
natural killer cells also contribute to allergic 
asthma by antigen presentation or cytokine 
release. In non-allergic asthma, pathways 
independent of TH2 are activated. These 
involve other cell types like neutrophils, 
alveolar macrophages but also natural killer 
cells (Kim et al., 2010). Airway epithelial 
cells also contribute to asthma develop-
ment, for instance as producers of inflam-
matory and anti-inflammatory cytokines 
involved in development of both allergic 
and non-allergic asthma (Kim et al., 2010; 
Wang et al., 2008). 
The three PPAR isotypes are expressed 
in many of the lung and immune cells be-
lieved to be involved in asthma develop-
ment and exacerbation, including airway 
epithelium, smooth muscle cells, macro-
phages, T lymphocytes and eosinophils 
(Becker et al., 2006; Di Paola and 
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Cuzzocrea, 2007). PPARs are involved in a 
variety of biological processes in these cell 
types. For instance, PPARα and γ ligands 
inhibit production of a number of inflam-
matory mediators and cytokines in several 
tissues and cell types including both lung 
cells and immune cells, with inhibition of 
transcriptional activity of inflammatory 
genes as a proposed mechanism (Di Paola 
and Cuzzocrea, 2007; Standiford et al., 
2005; Becker et al., 2006). Compared to 
PPARα and γ, relatively little is known 
about the role of PPARδ/β in the regulation 
of inflammatory responses (Zingarelli et al., 
2010), although some studies report that 
PPARδ/β agonists inhibit inflammatory re-
sponses both in vivo and in vitro (Schnegg 
and Robbins, 2011; Cuzzocrea, 2006).  
In addition to these anti-inflammatory 
effects, PPARα and γ are involved in regu-
lation of apoptosis, chemotaxis, pro-
liferation and differentiation in lung and 
immune cells (Becker et al., 2006). More-
over, PPARγ mediates an important role in 
surfactant homeostasis in alveolar type 2 
cells and in surfactant catabolism in alveo-
lar macrophages (Yang et al., 2008; Baker 
et al., 2010). A recent study reported that 
PPARγ, but not PPARα and δ/β, promoted 
monocyte differentiation towards alterna-
tively activated macrophages (AAMs or 
M2) (Bouhlel et al., 2009). A role of AAMs 
in chronic lung disease like asthma and 
COPD has been suggested, but it is still un-
clear whether these macrophages are the 
cause or the effect of these lung diseases 
(Byers and Holtzman, 2010).  
Thus, PPARs are mainly involved in an-
ti-inflammatory and beneficial responses in 
the lung. Since asthma development in-
volves various inflammatory processes, 
PPARs do not appear to play an obvious 
role in asthma development. Moreover 
PPAR agonists have been suggested as 
treatment of inflammatory lung diseases 
(Becker et al., 2006; Di Paola and 
Cuzzocrea, 2007; Cuzzocrea, 2006), further 
supporting that PPAR activation appears to 
have a beneficial effect in the airways ra-
ther than contributing to development of 
pulmonary diseases like asthma. 
 
IS PPAR ACTIVATION A LIKELY 
MECHANISM FOR PULMONARY 
EFFECTS OF PHTHALATES? 
As summarized in the introduction, pre-
sent epidemiological data support an asso-
ciation between phthalate exposure and res-
piratory symptoms including asthma, while 
experimental studies report that phthalates 
may induce an inflammatory response in 
lung- and immune cells. Furthermore, re-
cent studies have shown that phthalates may 
have a direct effect on airway epithelial 
cells and contribute to airway remodeling, 
which is the cardinal pathologic characteris-
tic of chronic asthma, with a high correla-
tion with disease severity (Tsai et al., 2012).  
PPARs have been identified as im-
portant targets for phthalates in the liver of 
some rodents and have also been suggested 
as a possible mechanism for phthalate-
induced effects in the lungs (Magliozzi et 
al., 2003; Rosicarelli and Stefanini, 2009; 
Just et al., 2012). The present literature re-
view of inhalation exposure to phthalates 
and the phthalate-induced activation of 
PPARs, suggests that for highly exposed 
individuals, metabolites of DnBP and 
DEHP may be present in the lungs at suffi-
cient concentrations for a direct “classical” 
activation of PPARs, but only when assum-
ing a high extent of pulmonary metabolism 
(hydrolysis). The extent of phthalate me-
tabolism in human lungs is presently un-
known, but a rapid absorption to the blood 
stream as well as a low pulmonary metabo-
lism has been suggested (Carlson, 2010). 
Based on the limited data available for a 
direct activation of PPARs by DnBP (low-
est binding concentrations, Lapinskas et al., 
2005), a direct activation PPARα and γ also 
appears to be possible since the estimated 
pulmonary phthalate concentrations were 
higher than the reported lowest binding 
concentrations. For the “new” high molecu-
lar weight phthalates like DiNP and DiDP, 
the inhalation exposure is not well charac-
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terised and it is therefore not possible to 
draw any conclusions regarding the likeli-
hood of phthalate-induced activation of 
PPAR due to inhalation exposure. For the 
low molecular phthalates, other than DnBP, 
the pulmonary concentrations of metabo-
lites or parent compound do not appear to 
be sufficient for a direct activation of 
PPARs. Overall, some phthalates may be 
inhaled in sufficient amounts to cause a di-
rect “classical” activation of PPARs, how-
ever, when considering that PPARs mainly 
mediate anti-inflammatory effects, it seems 
unlikely that a direct activation of these nu-
clear receptors are involved in adverse pul-
monary effects of phthalates. 
In contrast to a direct activation of 
PPARs, other modes of action may occur at 
lower concentrations and could be more 
relevant for eventual pulmonary effects of 
phthalates through PPAR. These modes 
may include modulation of PPAR activity 
e.g. via inhibition due to partial agonist ef-
fects, cross talk between pathways and/or 
possibly more direct effects through other 
signalling pathways (see chapter Inhibito-
ry or modulating effects of phthalates on 
PPAR activity). As activation of PPARs 
predominantly has anti-inflammatory ef-
fects, an inhibitory effect due to a partial 
agonist would interrupt the anti-
inflammatory signalling and therefore pos-
sibly contribute to inflammatory effects. 
Compounds like phthalates, inducing lower 
PPAR activity than full agonists, could thus 
interfere with the anti-inflammatory and 
beneficial effects of endogenous PPAR ac-
tivation and be a possible mechanism for 
pro-inflammatory effects of phthalates in 
the lung (see chapter Inhibitory or modu-
lating effects of phthalates on PPAR ac-
tivity). So far, the efficacy of phthalates has 
only been compared to that of the synthetic 
PPAR agonists, not to the efficacy of the 
endogenous PPAR ligands. Moreover, a 
partial agonist effect might be more likely 
to occur for the low- than the high-
molecular weight phthalates since the for-
mer generally have a lower efficacy (Ta-
ble 3). For the high molecular weight 
phthalates, that are more potent activators 
of PPARs, a more likely mode of action 
may be cross talk with other signalling 
pathways upon PPAR activation and/or 
dysregulation of gene transcription after 
phthalate-induced activation of PPARs 
causing a different transcriptional activation 
as compared to the endogenous PPAR lig-
ands (Feige et al., 2007; Desvergne et al., 
2009). Interestingly, polymorphisms of the 
PPARG gene may be linked to an increased 
risk for asthma development and airway 
hyper-reactivity (Lee et al., 2011; Oh et al., 
2009; Palmer et al., 2007); supporting that 
PPAR dysfunction could contribute to pul-
monary effects. However, more studies are 
necessary to clarify if modulatory or inhibi-
tory effects could contribute to phthalate-
induced pulmonary effects including devel-
opment and exacerbation of asthma. 
 
OTHER POSSIBLE MECHANISMS 
FOR PHTHALATE INDUCED 
PULMONARY EFFECTS 
Other exposure routes than inhalation 
may contribute to pulmonary effects. In line 
with this, a recent experimental study re-
ported that ingestion of DEHP caused 
changes in inflammatory biomarkers in the 
lungs of mice, as well as in pulmonary his-
tology and function, suggesting both adju-
vant effect on airway allergy and a pulmo-
nary inflammation (Guo et al., 2012). The 
applied concentrations were within the 
maximal estimated exposure range for hu-
man DEHP intake (Wormuth et al., 2006). 
Thus, ingestion may also be a relevant ex-
posure route for induction of effects in the 
airways and the immune system. Likewise, 
several epidemiological studies report asso-
ciations between urinary metabolite levels 
of phthalates and various pulmonary ef-
fects; some of these studies report associa-
tions for phthalates where ingestion is the 
major exposure route. Recent studies have 
indicated that dermal exposure may account 
for more than 50 % of the phthalate uptake 
from indoor air, thus this exposure route 
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also deserves further investigations with 
regard to possible airway effects of 
phthalates (Weschler and Nazaroff, 2012; 
Beko et al., 2013). 
The molecular mechanisms of phthalate 
toxicity are likely to vary depending not 
only on health endpoint and organ, but also 
on the species investigated. In support of 
this, a recent study of interactions between 
16 phthalates and genes/proteins from the 
Comparative Toxicogenomics Database 
(CDT) identified that the interactions dif-
fered between rodents and humans (Singh 
and Li, 2011). Moreover, when grouping 
the gene-protein interactions for DBP/BBP/ 
MBP and DEHP/MEHP; DEHP/MEHP had 
many interactions with PPARs, whereas 
DBP/BBP/MBP interacted more frequently 
with estrogen and androgen receptors. This 
implies that the effects of the individual 
phthalates are likely to be related to differ-
ent molecular mechanisms, rather than be-
ing related to one common mechanism.  
Several recent studies have addressed 
other mechanisms than PPAR activation 
with regard to phthalate induced effects. 
For instance, both DnBP and its metabolite 
MnBP were reported to bind directly to an-
tioxidant superoxide dismutase (SOD) and 
thereby interfere with the free radical scav-
enging capacity of this enzyme, with DnBP 
as the most potent inhibitor (Prasanth et al., 
2009). Direct binding to cyclooxygenase 
enzymes (COX) has also been reported for 
DnBP and other low molecular weight 
phthalates, with inhibition of the prosta-
glandin pathway as a possible consequence. 
This could have implications for immuno-
logical disorders (Kristensen et al., 2011). 
Moreover, Phthalate diesters were reported 
to interact with the two nuclear receptors 
Constitutive Androstane Receptor (CAR) 
and Pregnane X Receptor (PXR), that are 
known to be involved in the response to en-
dobiotics and xenobiotics, including tran-
scription and activation of detoxification 
enzymes (DeKeyser et al., 2011; Eveillard 
et al., 2009). DEHP and DiNP were howev-
er more potent activators of CAR than 
PXR. Interestingly, DEHP activated CAR2 
at very low concentrations, down to 10 nM 
in transactivation experiments (DeKeyser et 
al., 2011). The ligand-activated transcrip-
tion factor Aryl hydrocarbon Receptor 
(AhR) has also been reported to be stimu-
lated by parent phthalates (Mankidy et al., 
2013; Hsieh et al., 2012). Although these 
enzymes and receptors represent possible 
molecular mechanisms for biological ef-
fects of phthalates, their involvement in 
phthalate effects in the lung and immune 
system has not been elucidated. Since the 
pulmonary metabolism of phthalates might 
be low, it is however interesting to note that 
the majority of these other molecular mech-
anisms appear to be activated by parent 
phthalates rather than their metabolites. 
 
CONCLUSION 
Current epidemiological and experi-
mental knowledge suggests that phthalates 
could contribute to the development and 
exacerbation of asthma. If PPARs provide a 
mechanistic link between phthalate expo-
sure and asthma, the most likely scenario 
would be through antagonistic actions or 
modulatory effects since a direct PPAR ac-
tivation results in anti-inflammatory events. 
Other molecular mechanisms have been 
suggested for adverse effects of phthalates 
in other organs and cell types. These mech-
anisms may be equally relevant candidates 
in the development and exacerbation of 
asthma and airway hypersensitivity. Over-
all, further studies are still required to elu-
cidate the mechanisms involved in 
phthalate-induced pulmonary effects. The 
role of other phthalate exposure routes such 
as ingestion and dermal exposure for airway 
related effects should also be addressed in 
future studies. 
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